Business Context and Reporting Period
Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2025
Event: Regulation FD Disclosure regarding a corporate presentation titled "Belapectin for MASH Cirrhosis and Portal Hypertension."
Key Financial Metrics
This filing is a disclosure of a corporate presentation and does not contain audited financial statements, revenue figures, profit data, cash flow statements, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
No material changes to financial position or operations are reported in this document. The filing serves solely to disseminate the attached presentation and announce a webcast event.
Guidance, Outlook, and Risks
- Management Commentary: The Company posted a presentation on its website and hosted a webcast on June 16, 2025, at 12:00 p.m. ET regarding its drug candidate Belapectin.
- Forward-Looking Statements: The filing and the attached Exhibit 99.1 contain forward-looking statements based on current expectations. These are not guarantees of future performance.
- Risks: Actual events or results may differ materially from those in the forward-looking statements. The information is deemed "furnished" and not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the content of the "Belapectin for MASH Cirrhosis and Portal Hypertension" presentation (Exhibit 99.1) for specific clinical data or trial timelines.
- Confirm the availability of the webcast replay via the provided link (lifescievents.com/event/galectin/).
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.
- Monitor subsequent filings for any updates on the regulatory status of Belapectin.